UCB has announced its consolidated half year 2012 financial results. The first half year was marked by continuous execution and growth of core medicines Cimzia® (certolizumab pegol), Vimpat® (lacosamide) and Neupro® (rotigotine) with combined net sales total exceeding EUR 413 million (+45%).

Pfizer Inc. (NYSE: PFE) reported financial results for second-quarter 2012. Second-quarter 2012 revenues were $15.1 billion, a decrease of 9% compared with $16.5 billion in the year-ago quarter, which reflects an operational decline of $977 million, or 6%, and the unfavorable impact of foreign exchange of $451 million, or 3%.

Sales of the Bayer Group grew by 10.0 percent in the second quarter, to EUR 10,177 million (Q2 2011: EUR 9,252 million). The currency- and portfolio-adjusted (Fx & portfolio adj.) increase was 5.0 percent. The operating result (EBIT) fell by 41.1 percent to EUR 750 million (Q2 2011: EUR 1,273 million).

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the BREVACTA study of RoACTEMRA (tocilizumab, known as ACTEMRA outside Europe) given as a subcutaneous (SC) injection to patients with rheumatoid arthritis (RA) met its primary endpoint.

Amgen (NASDAQ:AMGN) announced financial results for the second quarter of 2012. Key results for the quarter include: Total revenues increased 13 percent to $4,477 million, with 8 percent product sales growth driven by strong performance across the portfolio;

AstraZeneca revenue for the second quarter was $6,660 million, down 18 percent at constant exchange rates (CER). Revenue declined by 21 percent on an actual basis as a result of the negative impact of exchange rate movements.

Eli Lilly and Company (NYSE: LLY) today announced financial results for the second quarter of 2012: Worldwide revenue declined 10 percent to $5.6 billion, driven by Zyprexa patent expirations, partially offset by significant growth in other products;